BioXcel Therapeutics (BTAI) Restructuring Costs (2023 - 2025)

BioXcel Therapeutics' Restructuring Costs history runs 3 years deep, the most recent figure standing at $194000.0 for Q3 2025.

• On a quarterly basis, Restructuring Costs fell 87.51% year-over-year to $194000.0 in Q3 2025; TTM through Dec 2025 was $227000.0, a 90.7% decrease from a year earlier, with the FY2025 full-year figure at $194000.0, down 92.05% from the prior year.
• Restructuring Costs grew to $194000.0 in Q3 2025 per BTAI's latest filing, from $33000.0 in the prior quarter.
• Across five years, Restructuring Costs topped out at $4.2 million in Q3 2023 and bottomed at $33000.0 in Q4 2024.
• The 3-year median for Restructuring Costs is $856000.0 (2024), against an average of $1.4 million.
• Across the five-year window, Restructuring Costs slumped 62.7% in 2024 and tumbled 87.51% in 2025, its largest moves.
• Year by year, Restructuring Costs stood at $4.2 million in 2023, then slumped by 99.21% to $33000.0 in 2024, then surged by 487.88% to $194000.0 in 2025.
• Per Business Quant, the three latest BTAI Restructuring Costs figures stand at $194000.0 (Q3 2025), $33000.0 (Q4 2024), and $1.6 million (Q3 2024).